Valeant's Paulson Boost, Plus 2 Rival Drug Stocks Moving Big on Trial Data

Hedge fund manager John Paulson is taking a seat on the Valeant Pharmaceuticals board

Managing Editor
Jun 19, 2017 at 10:40 AM
facebook twitter linkedin

U.S. stocks are rising today, boosted by big-cap tech names. Among specific names on the move today are drug stock Valeant Pharmaceuticals Intl Inc (NYSE:VRX), cancer treatment developer Clovis Oncology Inc (NASDAQ:CLVS), and drugmaker TESARO Inc (NASDAQ:TSRO). Here's a quick look at what's moving shares of VRX, CLVS, and TSRO.

Board Addition Boosts VRX Stock

Valeant Pharmaceuticals stock jumped 3% to trade at $13.07, after news broke that hedge fund manager John Paulson was elected to the company's board of directors. Paulson's own hedge fund is Valeant's largest shareholder.

VRX is down 10% year-to-date, and the stock is staring up at its 150-day moving average, which capped a mid-May rally attempt. However, with the shares up 57% from April's eight-year low of $8.31, options traders are favoring calls. Data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) shows VRX with a 50-day call/put volume ratio of 2.83, ranking in the 97th percentile of its annual range.

Upbeat Drug Data Sends CLVS Stock Soaring

Clovis Oncology stock is roaring today, up 40% to trade at $84.92, after its ovarian cancer drug Rubraca delivered positive results in a late-stage study. Clovis plans to submit the drug for a label expansion soon, which would allow the treatment to be used for longer periods in a wider range of patients. The boost today sends CLVS stock to an 18-month high of $91, with the stock bouncing strongly off its 80-day moving average.

Heading into today's announcement, options traders were bracing for big moves from CLVS. The equity's Schaeffer's Volatility Index (SVI) of 1.50 rates higher than 90% of all other readings from the past year, indicating that front-month options have priced in higher volatility expectations only 10% of the time during the past year.

TSRO Stock Stumbles After Rival Drug Study Succeeds

Tesaro stock is down 6% to trade at $135.22, after rival Clovis Oncology reported positive results for its cancer treatment drug. TSRO shares have been declining steadily from their Feb. 21 all-time high of $192.94, and today's drop has the stock on pace to close below its 200-day moving average for the first time since its big bullish gap in June 2016.

Analysts remain optimistic, however. Nine out of 16 brokerages covering TSRO stock rate it a "buy" or better, which leaves the door open for downgrades going forward.


If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial


Special Offers from Schaeffer's Trading Partners